← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ENDOCRINE THERAPY › HORMONE ANTAGONISTS AND RELATED AGENTS › Anti-androgens
bicalutamide
L02BB03
Adult Dosing
- Prostate cancer (advanced): 50 mg orally once daily in combination with an LHRH analog
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for stage D2 metastatic prostate carcinoma
Mechanism of Action
- Non-steroidal anti-androgen that competitively binds to androgen receptors in target tissues, inhibiting the stimulatory effects of androgenic hormones
Contraindications
- Hypersensitivity to bicalutamide or any component of the product
- Pregnancy (Category X)
- Use in females
Adverse Reactions
- Hot flashes
- Gynaecomastia and breast pain
- Asthenia
- Diarrhea, nausea, and abdominal pain
- Elevated transaminases and hepatotoxicity
- Anemia
- Decreased libido and impotence
Drug Interactions
- Coumarin anticoagulants: May increase the anticoagulant effect; monitor PT/INR closely
- CYP3A4 inhibitors/inducers: Bicalutamide is primarily metabolized by CYP3A4 (via CYP3A4 oxidation and glucuronidation)
Curated Content: Needs Vetting Before Put to Clinical Use